Investment Trusts

BioPharma Credit PLC

BPCR:LSE

BioPharma Credit PLC

Actions
  • Price (USD)0.856
  • Today's Change-0.012 / -1.38%
  • Shares traded220.03k
  • 1 Year change+4.39%
  • Beta0.2924
Data delayed at least 20 minutes, as of Nov 11 2024 13:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Total returns on $1000

1Y
Fund/benchmarkChange
PriceBioPharma Credit PLC (Ordinary Share)+23.53%
NAVBioPharma Credit PLC (Ordinary Share)+21.43%
Morningstar's BenchmarkNo benchmark--

Key statistics

As of last trade BioPharma Credit PLC (BPCR:LSE) traded at 0.856, 5.03% above its 52-week low of 0.815, set on Nov 13, 2023.
52-week range
Today
0.815Nov 13 20230.944Jan 30 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding1.19bn
Market cap1.03bn USD
Total assets1.17bn USD
Total expense ratio1.15%
High0.87
Low0.856
Previous close0.868
Average volume1.14m
YTD Change+1.90%
Beta0.2924
Diluted NAV (est)0.9804
Diluted NAV (last pub)0.9723
Premium/Discount-11.47%
Net Gearing0.00%
Annual div (ADY)0.07
USD
Annual div yield (ADY)8.06%
Div ex-dateSep 26 2024
Div pay-dateOct 29 2024
Data delayed at least 20 minutes, as of Nov 11 2024 13:55 GMT.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.